AlzeCure Pharma: Positive FDA feedback regarding ACD440 in orphan disease - Redeye
Bildkälla: Stockfoto

AlzeCure Pharma: Positive FDA feedback regarding ACD440 in orphan disease - Redeye

Redeye comments on yesterday’s news that AlzeCure has received positive feedback from the FDA regarding the clinical path for ACD440 in the rare pain disorder erythromelalgia.

Börsvärldens nyhetsbrev